분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-14 17:58:34 , Hit : 1065
 Gilead hepatitis C drug highly effective in cirrhosis patients


Reuters
By Ransdell Pierson
November 11, 2014 11:29 AM


      
By Ransdell Pierson

(Reuters) - Gilead Sciences Inc on Tuesday said its new Harvoni drug for hepatitis C achieved cure rates of 96 percent to 97 percent in a study of patients who had cirrhosis and had failed to benefit from prior treatments.

The data bolsters the attractiveness of Harvoni, a combination drug that U.S. regulators approved last month and whose $95,000 cost for a course of treatment has raised complaints from insurers and politicians.

The Gilead study involved 155 patients with cirrhosis and the most common genotype 1 form of the liver virus. They previously had failed to benefit from standard older treatments that included protease inhibitors as well as interferon and ribavirin, drugs that can cause harsh side effects and must be taken for almost a year.

All patients received Harvoni, a once-daily pill containing Gilead's Sovaldi and ledipasvir. The combination eliminates the need to take interferon and ribavirin with Sovaldi.

In one group taking Harvoni alone for 24 weeks, the cure rate was 97 percent. It was 96 percent for patients who received Harvoni plus ribavirin for 12 weeks.

Three far smaller Gilead studies evaluated Sovaldi, a so-called nucleotide, in combination with the company's experimental NS5A inhibitor GS-5816, with and without ribavirin for eight or 12 weeks.

Of patients taking the combination for 12 weeks without ribavirin, sustained cures were seen in 100 percent of genotype 1 patients, with and without cirrhosis, and in 88 percent of those with the less common genotype 3 form of the virus, with cirrhosis.

Shares of Gilead were up 1.4 percent at $108.54 in morning trading.

(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)







1087   microRNA가 췌장암 치료제가 될 수 있을까  이성욱 2015/06/30 1052
1086   Drug flushes out hidden AIDS virus  이성욱 2015/03/07 1053
1085   융합연구리뷰 | Convergence Research Review  이성욱 2016/01/08 1057
1084   정밀의학의 끝: 개인화된 종양백신을 개발하는 과학자들  이성욱 2016/04/26 1059
1083   [바이오토픽] 브로드 연구소, 열띤 CRISPR 특허전쟁에서 승리  이성욱 2017/02/16 1060
  Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1065
1081   유전자치료제 연구개발 및 규제 동향 2015-식품의약품안전처  이성욱 2016/01/20 1065
1080   [바이오토픽] C형간염을 3주 만에 치료하는 DAA 3제요법  이성욱 2015/11/02 1070
1079   진화와 질병치료 연구를 진전시킬 새로운 유전 메커니즘  이성욱 2015/02/06 1072
1078   미국 과학·공학·의학 아카데미, 「GM 베이비」의 진행방향에 대한 윤곽 발표  이성욱 2017/02/16 1072
1077   일본의 검증팀 STAP 세포 재현 포기, 오보카타 사임  이성욱 2014/12/23 1074
1076   세계 20여 개국 과학자들, 유전자편집 정상회담 개최  이성욱 2015/12/05 1079
1075   CRISPR Structure Data Reveal How Cas Enzymes Choose Target  이성욱 2017/07/25 1086
1074   옥스포드 나노포어, 휴대용 시퀀서 미니온 출시 임박  이성욱 2015/05/08 1090
1073   암 생존율을 높일 수 있는 면역세포  이성욱 2014/12/16 1091
1072   네안데르탈인과 이웃에 살았던 현생인류의 두개골 발견  이성욱 2015/02/03 1095
1071   Chinese Scientists To Test Gene Modifying Technique ‘CRISPR’ On Humans For The First Time  이성욱 2016/07/27 1095
1070   [미국] 유전자가위 규제 마련 지연과 기업들의 움직임  이성욱 2016/07/21 1104
1069   유전자편집치료에 희망을 준 백혈병치료  이성욱 2015/11/11 1107
1068   부모의 특징을 자식에게 전달하는 방식: 박테리아의 DNA  이성욱 2015/02/19 1108

[1][2][3][4][5][6][7][8][9] 10 ..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN